SKYE — Skye Bioscience Income Statement
0.000.00%
- $165.32m
- $85.77m
- 37
- 24
- 65
- 37
Annual income statement for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.36 | 6.29 | 7.73 | 18.8 | 35.1 |
Operating Profit | -7.36 | -6.29 | -7.73 | -18.8 | -35.1 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.05 | -6.56 | -8.52 | -19.5 | -37.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.05 | -6.56 | -8.52 | -19.5 | -37.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.05 | -6.56 | -8.52 | -19.5 | -37.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.05 | -6.56 | -8.52 | -19.5 | -37.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.29 | -7.11 | -5.29 | -6.82 | -5.32 |